For patients with metastatic castration-resistant prostate cancer, treatment with rucaparib is associated with significantly longer duration of imaging-based progression-free survival compared with a control medication, according to a study published online Feb. 16 in the New England Journal of Medicine to coincide with the American Society of Clinical Oncology annual Genitourinary Cancers Symposium, held from Feb. 16 to 18 in San Francisco.
https://www.lifetechnology.com/blogs/life-technology-medical-news/rucaparib-efficacious-in-metastatic-castration-resistant-prostate-cancer
Buy SuperforceX™
